Your session is about to expire
← Back to Search
Pembrolizumab and Radiation for Non-Small Cell Lung Cancer
Study Summary
This trial is testing whether adding radiation to a drug regimen can help shrink tumors in people with advanced lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical conditions is Pembrolizumab commonly employed to address?
"Pembrolizumab is often administered to treat malignant neoplasms, in addition to unresectable melanoma and chemotherapy-resistant tumors with high microsatellite instability."
Are there any other investigations into the efficacy of Pembrolizumab?
"Currently, there are 961 active studies researching the potential of Pembrolizumab to treat various conditions. 122 trials have made it up to Phase 3 and in total 35727 sites across the world are conducting experiments on this medication. Houston, Texas is one such place with multiple research centres participating in these tests."
How many participants are included in this clinical investigation?
"This trial is no longer accepting patients. The study first appeared on the 6th of July 2017 and was last revised on 29th of July 2022. For those looking for alternative trials, there are currently 45 studies enrolling individuals with erythema multiforme and 961 clinical investigations seeking volunteers to receive Pembrolizumab treatment."
What potential risks are associated with Pembrolizumab treatment?
"There is limited clinical data demonstrating the safety of Pembrolizumab, thus it has been given a score of 2."
Is this clinical trial currently enrolling new participants?
"This clinical trial is currently not recruiting patients. It was first listed on June 7th 2017 and last edited on July 29th 2022. If you're looking for other studies, 45 trials are accepting enrolments from individuals with erythema multiforme, while 961 research projects need participants to investigate pembrolizumab."
Share this study with friends
Copy Link
Messenger